Guggenheim Capital’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.7M | Sell |
49,213
-277
| -0.6% | -$11.3K | 0.02% | 632 |
|
|
2026
Q1 | $1.64M | Sell |
49,490
-16,561
| -25% | -$494K | 0.01% | 776 |
|
|
2025
Q4 | $1.97M | Buy |
66,051
+27,303
| +70% | +$892K | 0.01% | 679 |
|
|
2025
Q3 | $1.4M | Buy |
38,748
+2,328
| +6% | +$76.7K | 0.01% | 809 |
|
|
2025
Q2 | $1.31M | Buy |
36,420
+511
| +1% | +$19K | 0.01% | 794 |
|
|
2025
Q1 | $1.42M | Sell |
35,909
-5,552
| -13% | -$187K | 0.01% | 758 |
|
|
2024
Q4 | $1.25M | Sell |
41,461
-14,905
| -26% | -$428K | 0.01% | 819 |
|
|
2024
Q3 | $1.32M | Sell |
56,366
-1,776
| -3% | -$38.8K | 0.01% | 976 |
|
|
2024
Q2 | $1.03M | Sell |
58,142
-3,052
| -5% | -$48.7K | 0.01% | 1100 |
|
|
2024
Q1 | $931K | Buy |
61,194
+2,447
| +4% | +$39K | 0.01% | 1219 |
|
|
2023
Q4 | $1M | Sell |
58,747
-19,805
| -25% | -$230K | 0.01% | 1162 |
|
|
2023
Q3 | $657K | Buy |
78,552
+30,369
| +63% | +$423K | 0.01% | 1299 |
|
|
2023
Q2 | $1.2M | Sell |
48,183
-21,403
| -31% | -$553K | 0.01% | 1076 |
|
|
2023
Q1 | $1.05M | Buy |
+69,586
| New | +$1.06M | 0.01% | 1158 |
|
|
2022
Q2 | – | Sell |
-111,655
| Closed | -$1.06M | – | 2130 |
|
|
2022
Q1 | $1.06M | Buy |
111,655
+24,076
| +27% | +$279K | 0.01% | 1334 |
|
|
2021
Q4 | $1.66M | Buy |
87,579
+23,336
| +36% | +$606K | 0.01% | 1151 |
|
|
2021
Q3 | $2.14M | Buy |
64,243
+6,623
| +11% | +$205K | 0.01% | 1022 |
|
|
2021
Q2 | $2.23M | Buy |
57,620
+5,584
| +11% | +$219K | 0.01% | 1035 |
|
|
2021
Q1 | $2.51M | Buy |
+52,036
| New | +$2.5M | 0.02% | 917 |
|
|
2018
Q2 | – | Sell |
-74,974
| Closed | -$1.06M | – | 2583 |
|
|
2018
Q1 | $1.06M | Sell |
74,974
-76,413
| -50% | -$977K | ﹤0.01% | 2047 |
|
|
2017
Q4 | $1.24M | Buy |
151,387
+49,452
| +49% | +$432K | ﹤0.01% | 1970 |
|
|
2017
Q3 | $1.21M | Buy |
101,935
+212
| +0.2% | +$2.42K | ﹤0.01% | 1992 |
|
|
2017
Q2 | $1.02M | Sell |
101,723
-10,200
| -9% | -$114K | ﹤0.01% | 2076 |
|
|
2017
Q1 | $1.3M | Sell |
111,923
-156,062
| -58% | -$1.12M | ﹤0.01% | 1950 |
|
|
2016
Q4 | $1.25M | Buy |
267,985
+108,106
| +68% | +$634K | ﹤0.01% | 2019 |
|
|
2016
Q3 | $1.24M | Sell |
159,879
-4,334
| -3% | -$27.9K | ﹤0.01% | 1959 |
|
|
2016
Q2 | $995K | Buy |
164,213
+44,192
| +37% | +$359K | ﹤0.01% | 2062 |
|
|
2016
Q1 | $1.02M | Buy |
120,021
+5,097
| +4% | +$44.6K | ﹤0.01% | 2037 |
|
|
2015
Q4 | $1.37M | Sell |
114,924
-3,430
| -3% | -$43.3K | ﹤0.01% | 1903 |
|
|
2015
Q3 | $1.19M | Buy |
+118,354
| New | +$1.76M | ﹤0.01% | 1981 |
|
Other funds holding TGTX
SCM
CAM
Guggenheim Capital's TGTX Position: Q2 2026 in Review
Guggenheim Capital reduced its TG Therapeutics (TGTX) stake by 0.56% in Q2 2026, selling an estimated $11.3K and leaving 49,213 shares worth $2.7M. The position accounts for 0.02% of the portfolio, ranked #632.
Guggenheim Capital first reported a position in TGTX in Q3 2015 and has held it in 30 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- Guggenheim Capital held 49,213 shares of TG Therapeutics worth $2.7M as of Q2 2026.
- Guggenheim Capital sold 277 TG Therapeutics shares in Q2 2026, an estimated $11.3K.
- TG Therapeutics made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #632 holding.
- Guggenheim Capital first reported a position in TG Therapeutics in Q3 2015 and has held it in 30 quarters since.
- 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.